Gene Therapy: The Current Codon Status by Sambasivam, Ganesh
Mapana J Sci, 14, 2 (2015), 19-21 
 ISSN 0975-3303|doi:10.12723/mjs.33.3  
19 
 
Gene Therapy: The Current Codon Status 
Ganesh Sambasivam* 
Scenes of scientists exploiting the genetic material from an amber 
trapped mosquito which had apparently sucked the blood of a 
ferocious dinosaur to finally create a monster had captured the 
imagination of audience world wide. Genetic engineering has since 
then gradually emerged from the shadows of fantastic and 
novelistic ideas depicted in the wildly successful Jurassic Park to the 
box-office flop Alien: Resurrection. The image of creating a 
seemingly flawless piece of genetic thread finely entwined 
following years of research spent in solving the genetic jigsaw has 
captured the imagination of the world. The implications are huge 
and often exaggerated but never thought to be beyond the reach of 
the ever-so impatient man. The impact of genetic engineering on 
the society is often debated but a final decision will unfortunately 
have to wait. 
Generally branded as monolithic, by the common man, genetic 
engineering is just a catchall phrase that depicts the tools used to 
efficiently and appropriately manipulate   an organism’s hereditary 
material.  The plethora of information released into the public 
domain from the human Genome project proved to be the lifeline 
for a therapy now touted to be the ‘medicine of the future’. What 
would appear to be a seemingly innocuous alteration in the 
nucleotide of a person’s genome (genetic make-up) has now been 
proved to be the underlying cause of thousands of genetic 
disorders. Most diseases can now be explained as manifestations of 
gene disorders. Herein lies the huge implications of a therapy that 
aims to set right the disorder/s caused due to genetic alterations.  
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Gene therapy involves the insertion of correct genes into an 
individual’s cell to treat a disease. This could be a hereditary 
disorder in which a functional gene/allele replaces a dysfunctional 
one leading to corrections in a person’s genetic make-up. Extensive 
studies worldwide have led to the identification of exact genetic 
alterations in the genome sequence that contributes to an array of 
diseases like Glaucoma, rheumatoid arthritis and schizophrenia. 
This therapy assumes huge significance given the prevalence of 
monogenic disorders like hemophilia, sickle cell anemia, muscular 
dystrophy and cystic fibrosis. Gene therapy could either refer to 
Germ line gene therapy or Somatic gene therapy. Germ line 
therapy refers to the introduction of functional genes into sperms 
or eggs hence; the change due to therapy is heritable. However, 
given the ethical and technical hurdles in this form of gene therapy 
applications in human beings has been prohibited. On the other 
hand Somatic gene therapy involves the transfer of therapeutic 
genes into somatic cells of a patient and will not be heritable.   
Worldwide experts are of the opinion that gene therapy’s current 
status is similar to that of monoclonal antibodies 15 years ago and 
that the net market worth is estimated to be over $ 20 billion. The 
world’s first commercialized gene therapy drug is Gendicine made 
by China’s Shenzhen SiBiono Gene Tech. Gendicine is now being 
reviewed by the Drugs Controller General of India (DCGI) which 
would then decide on allowing clinical trials in India. Known as 
Recombinant Ad-p53 Anti-cancer injection this drug is used to treat 
head and neck squamous cell carcinoma. Data from Indian clinical 
trials could help significantly in obtaining regulatory approvals in 
other developing and developed nations. The only other 
commercialized gene therapy product is Rexin G from Epeius 
Biotechnologies in California, currently approved for use only in 
the Philippines for treatment of metastatic breast cancer, pancreatic 
cancer, Osteosarcoma and soft tissue sarcoma.   HGF DNA 
plasmid, a drug from Sosei and Daiichi Sankyo investigated for 
treatment of peripheral vascular disease was filed for approval in 
Japan. Success in discrete medical trials has also been witnessed in 
treating conditions like myelination disorder X-linked ALD 
(adenoleukodystrophy), ADA-SCID (adenosine deaminase 
deficiency-related Severe Combined Immunodeficiency) and Leber 
congenital amaurosis).  
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Although gene therapy failed to live up to its promise in early 
1990s, it was generally accepted that the discouraging outcome was 
not due to an adequate insights into the genomics involved rather 
due to the lack of an optimal gene delivery system. Success in gene 
therapy has now been acknowledged as an outcome determined by 
optimal gene delivery systems. Retroviral vectors have long been 
used in gene therapy clinical trials. However, this system suffers 
from serious setbacks such as weak titers and inefficient 
encapsidation of the therapeutic gene, thus decreasing their 
therapeutic value. Unlike retroviruses, lentivectors do not 
necessarily require cell division for proviral integration. 
Lentivectors couple the advantage of facilitating a highly efficient 
and stable transgene expression to its ability to transduce a variety 
of cell types that are not amenable to transduction by other vectors. 
Although several clinical trials are currently on in several parts of 
the world, gene therapy still appears to be in the infancy stage in 
India. Studies are however being conducted for oral cancer at the 
Tata Memorial Hospital, Mumbai. Narayana Nethralaya, a 
speciality eye hospital in Bangalore is in the process of using gene 
therapy to treat inherited retinal disorders in children. Although a 
recent Financial Express report indicates that Intas Pharma will 
launch Gendicine in India, there appear to be no reports of any 
company in India that has taken the initiative to invest in and 
explore the potential of this remarkable technology. It is of 
paramount importance that gene therapy strategies and regulatory 
approvals be put in place urgently. This will facilitate appropriate 
therapeutic interventions that could potentially prove to be a boon 
to the millions that suffer from genetic disorders. 
